MX2021006970A - Analogos de insulina que tienen una afinidad de union disminuida al receptor de insulina. - Google Patents
Analogos de insulina que tienen una afinidad de union disminuida al receptor de insulina.Info
- Publication number
- MX2021006970A MX2021006970A MX2021006970A MX2021006970A MX2021006970A MX 2021006970 A MX2021006970 A MX 2021006970A MX 2021006970 A MX2021006970 A MX 2021006970A MX 2021006970 A MX2021006970 A MX 2021006970A MX 2021006970 A MX2021006970 A MX 2021006970A
- Authority
- MX
- Mexico
- Prior art keywords
- insulin
- binding affinity
- receptor binding
- reduced
- analogs
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 5
- 102000003746 Insulin Receptor Human genes 0.000 title 1
- 108010001127 Insulin Receptor Proteins 0.000 title 1
- 230000035772 mutation Effects 0.000 abstract 3
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 230000002209 hydrophobic effect Effects 0.000 abstract 2
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18306658 | 2018-12-11 | ||
| EP18306659 | 2018-12-11 | ||
| EP18306657 | 2018-12-11 | ||
| PCT/EP2019/084427 WO2020120477A1 (en) | 2018-12-11 | 2019-12-10 | Insulin analogs having reduced insulin receptor binding affinity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021006970A true MX2021006970A (es) | 2021-07-15 |
Family
ID=68806785
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021006970A MX2021006970A (es) | 2018-12-11 | 2019-12-10 | Analogos de insulina que tienen una afinidad de union disminuida al receptor de insulina. |
| MX2021006972A MX2021006972A (es) | 2018-12-11 | 2019-12-10 | Conjugados de insulina. |
| MX2021006969A MX2021006969A (es) | 2018-12-11 | 2019-12-10 | Ligante peptidico. |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021006972A MX2021006972A (es) | 2018-12-11 | 2019-12-10 | Conjugados de insulina. |
| MX2021006969A MX2021006969A (es) | 2018-12-11 | 2019-12-10 | Ligante peptidico. |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US11098102B2 (enExample) |
| EP (3) | EP3894435A1 (enExample) |
| JP (3) | JP2022513776A (enExample) |
| KR (3) | KR20210102347A (enExample) |
| CN (3) | CN113396157A (enExample) |
| AU (3) | AU2019398579A1 (enExample) |
| BR (3) | BR112021011050A2 (enExample) |
| CA (3) | CA3122632A1 (enExample) |
| CO (1) | CO2021007453A2 (enExample) |
| IL (3) | IL283803A (enExample) |
| MX (3) | MX2021006970A (enExample) |
| PH (1) | PH12021551339A1 (enExample) |
| SG (3) | SG11202106167XA (enExample) |
| TW (3) | TW202039438A (enExample) |
| WO (3) | WO2020120479A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210102347A (ko) | 2018-12-11 | 2021-08-19 | 사노피 | 인슐린 수용체 결합 친화성이 감소된 인슐린 유사체 |
| CN112876388B (zh) * | 2021-01-14 | 2023-03-31 | 山东大学 | 一种gpr120激动剂及其制备方法与应用 |
| CN116162147B (zh) * | 2021-11-24 | 2023-10-03 | 成都奥达生物科技有限公司 | 一种长效胰岛素类似物 |
| CN114230451A (zh) * | 2021-12-29 | 2022-03-25 | 上海药坦药物研究开发有限公司 | 卤代酸类化合物的制备方法 |
| EP4469088A1 (en) * | 2022-01-26 | 2024-12-04 | Sanofi | Insulin conjugates |
| JP2025522529A (ja) | 2022-06-23 | 2025-07-15 | サノフイ | 一本鎖インスリン及びそのＦｃ結合体 |
| CN115947822B (zh) * | 2022-07-04 | 2023-08-18 | 北京惠之衡生物科技有限公司 | 一种长效酰化胰岛素衍生物及其药物组合物和应用 |
| WO2024051787A1 (zh) * | 2022-09-09 | 2024-03-14 | 北京惠之衡生物科技有限公司 | 一种长效酰化胰岛素衍生物及其应用 |
| CN118063589A (zh) * | 2024-02-04 | 2024-05-24 | 乐普健糖药业(重庆)有限公司 | 一种超长效胰岛素类似物及其制备方法和用途 |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1132404A3 (en) | 1993-09-17 | 2002-03-27 | Novo Nordisk A/S | Acylated insulin |
| CZ289343B6 (cs) | 1995-03-17 | 2002-01-16 | Novo Nordisk A/S | Inzulinový derivát a farmaceutický prostředek pro léčení diabetes |
| US6451970B1 (en) | 1996-02-21 | 2002-09-17 | Novo Nordisk A/S | Peptide derivatives |
| JP2001521006A (ja) | 1997-10-24 | 2001-11-06 | イーライ・リリー・アンド・カンパニー | 不溶性インシュリン組成物 |
| CA2572770A1 (en) | 2004-07-08 | 2006-01-19 | Novo-Nordisk A/S | Polypeptide protracting tags comprising a tetrazole moiety |
| US20080171695A1 (en) | 2005-02-02 | 2008-07-17 | Novo Nordisk A/S | Insulin Derivatives |
| EP2256130B1 (en) | 2005-02-02 | 2013-09-25 | Novo Nordisk A/S | Novel insulin derivatives |
| CN102660614A (zh) | 2005-08-16 | 2012-09-12 | 诺沃-诺迪斯克有限公司 | 制备成熟胰岛素多肽的方法 |
| DE602007009496D1 (de) | 2006-02-27 | 2010-11-11 | Novo Nordisk As | Insulinderivate |
| WO2007104736A2 (en) | 2006-03-13 | 2007-09-20 | Novo Nordisk A/S | Acylated single chain insulin |
| EP2015770B1 (en) | 2006-05-09 | 2012-09-26 | Novo Nordisk A/S | Insulin derivative |
| WO2007128815A1 (en) | 2006-05-09 | 2007-11-15 | Novo Nordisk A/S | Insulin derivative |
| CN101573133B (zh) | 2006-07-31 | 2014-08-27 | 诺沃-诺迪斯克有限公司 | Peg化延长的胰岛素 |
| RU2524150C2 (ru) | 2006-09-22 | 2014-07-27 | Ново Нордиск А/С | Аналоги инсулина, устойчивые к протеазам |
| WO2008049711A1 (en) | 2006-10-27 | 2008-05-02 | Novo Nordisk A/S | Peptide extended insulins |
| GB0621973D0 (en) | 2006-11-03 | 2006-12-13 | Philogen Spa | Binding molecules and uses thereof |
| EP1974729A1 (en) * | 2007-03-28 | 2008-10-01 | Santhera Pharmaceuticals (Schweiz) AG | Substituted imidazopyridine derivates as melanocortin- 4 receptor antagonists |
| JP5688969B2 (ja) | 2007-07-16 | 2015-03-25 | ノボ・ノルデイスク・エー／エス | プロテアーゼに対して安定しているペグ化インスリンアナログ |
| JP5721432B2 (ja) | 2007-08-15 | 2015-05-20 | ノボ・ノルデイスク・エー／エス | アミノ酸含有アルキレングリコール反復単位を含むアシル部を有するインスリン |
| US9150633B2 (en) | 2007-08-15 | 2015-10-06 | Novo Nordisk A/S | Insulin analogues with an acyl and alkylene glycol moiety |
| MX2010005317A (es) | 2007-11-20 | 2010-06-02 | Ambrx Inc | Polipeptidos de insulina modificados y sus usos. |
| WO2009112583A2 (en) | 2008-03-14 | 2009-09-17 | Novo Nordisk A/S | Protease-stabilized insulin analogues |
| HUE032284T2 (en) * | 2008-03-18 | 2017-09-28 | Novo Nordisk As | Protease-stabilized, acylated insulin analogues |
| CN102065903B (zh) | 2008-04-01 | 2015-02-18 | 诺沃-诺迪斯克有限公司 | 胰岛素清蛋白缀合物 |
| PL219335B1 (pl) * | 2008-07-04 | 2015-04-30 | Inst Biotechnologii I Antybiotyków | Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna |
| JP4959005B2 (ja) | 2008-10-30 | 2012-06-20 | ノボ・ノルデイスク・エー／エス | 毎日の注射頻度より少ないインスリン注射での真性糖尿病の治療 |
| JP2012511506A (ja) | 2008-12-09 | 2012-05-24 | ノヴォ・ノルディスク・アー／エス | 新規インスリンアナログ |
| JP5789515B2 (ja) | 2008-12-19 | 2015-10-07 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | インスリン類似体 |
| AU2009335715B2 (en) | 2008-12-19 | 2016-09-15 | Indiana University Research And Technology Corporation | Amide-based insulin prodrugs |
| WO2010130638A1 (en) * | 2009-05-14 | 2010-11-18 | Evotec Ag | Sulfonamide compounds, pharmaceutical compositions and uses thereof |
| CN107129538B (zh) * | 2010-04-27 | 2021-07-16 | 西兰制药公司 | Glp-1受体激动剂和胃泌素的肽缀合物及其用途 |
| MX2012012943A (es) | 2010-05-10 | 2012-11-29 | Novo Nordisk As | Proceso para preparacion de complejos de insulina-cinc. |
| EP2585102B1 (en) | 2010-06-24 | 2015-05-06 | Indiana University Research and Technology Corporation | Amide-based insulin prodrugs |
| WO2012049307A2 (en) | 2010-10-15 | 2012-04-19 | Novo Nordisk A/S | Novel n-terminally modified insulin derivatives |
| TWI574687B (zh) * | 2011-01-03 | 2017-03-21 | 古利斯股份有限公司 | 具有鋅結合部份之刺蝟拮抗劑 |
| CN103596584B (zh) | 2011-06-15 | 2016-12-14 | 诺沃—诺迪斯克有限公司 | 多取代的胰岛素 |
| KR20150021011A (ko) * | 2011-10-27 | 2015-02-27 | 케이스 웨스턴 리저브 유니버시티 | 초고도 농축된, 속효성 인슐린 유사체 제형 |
| CN104011070A (zh) | 2011-12-15 | 2014-08-27 | 爱德迪安（北京）生物技术有限公司 | 具有降血糖作用的化合物、组合物及其用途 |
| KR20140104994A (ko) | 2011-12-15 | 2014-08-29 | 샹하이 헨그루이 파마수티컬 컴퍼니 리미티드 | 인간 인슐린 유사체 및 이의 아실화 유도체 |
| US20140357838A1 (en) | 2011-12-21 | 2014-12-04 | Novo Nordisk A/S | N-Terminally Modified Insulin Derivatives |
| US20150111820A1 (en) | 2012-07-09 | 2015-04-23 | Novo Nordisk A/S | Novel use of insulin derivatives |
| AU2013337250B2 (en) | 2012-11-05 | 2017-06-22 | Case Western Reserve University | Long-acting single-chain insulin analogues |
| DK2963056T3 (da) | 2013-02-26 | 2020-02-17 | Hanmi Pharm Ind Co Ltd | Insulinanalog og anvendelse deraf |
| JP6538645B2 (ja) | 2013-03-14 | 2019-07-03 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | インスリン‐インクレチン複合物 |
| CN105188736A (zh) | 2013-03-20 | 2015-12-23 | 诺和诺德股份有限公司 | 胰岛素给药方案 |
| EP2991672A1 (en) | 2013-04-30 | 2016-03-09 | Novo Nordisk A/S | Novel administration regime |
| JP2016521701A (ja) | 2013-06-07 | 2016-07-25 | ノヴォ ノルディスク アー／エス | 成熟インスリンポリペプチドを作製するための方法 |
| JP6347451B2 (ja) * | 2013-08-02 | 2018-06-27 | 国立大学法人富山大学 | （ベンゼンスルホニルアミノ）ベンズアミド誘導体およびそれらを有効成分とするｓｈｉｐ２阻害剤 |
| WO2015095953A1 (en) | 2013-12-27 | 2015-07-02 | The Centre For Drug Research And Development | Sulfonamide-containing linkage systems for drug conjugates |
| CR20160376A (es) | 2014-01-20 | 2016-10-07 | Hanmi Pharm Ind Co Ltd | Insulina de acción prolongada y uso de la misma |
| AR099569A1 (es) | 2014-02-28 | 2016-08-03 | Novo Nordisk As | Derivados de insulina y los usos médicos de estos |
| AR100639A1 (es) * | 2014-05-29 | 2016-10-19 | Hanmi Pharm Ind Co Ltd | Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada |
| KR20160001391A (ko) | 2014-06-27 | 2016-01-06 | 한미약품 주식회사 | 신규한 지속형 인슐린 아날로그 결합체 및 이의 용도 |
| WO2016001185A1 (en) | 2014-07-02 | 2016-01-07 | Novo Nordisk A/S | Dosage regimen for the treatment of diabetes |
| KR20160007295A (ko) | 2014-07-11 | 2016-01-20 | 한미약품 주식회사 | 인슐린 아날로그 |
| WO2016119854A1 (en) | 2015-01-29 | 2016-08-04 | Novo Nordisk A/S | Pharmaceutical composition for oral insulin administration comprising a tablet core and a polyvinyl alcohol coating |
| WO2016172269A2 (en) | 2015-04-20 | 2016-10-27 | University Of Utah Research Foundation | Insulin analogs having shortened b chain peptides and associated methods |
| US20190010206A1 (en) | 2015-08-25 | 2019-01-10 | Novo Nordisk A/S | Novel Insulin Derivatives and the Medical Uses Hereof |
| US11097046B2 (en) | 2015-08-25 | 2021-08-24 | Novo Nordisk A/S | Medical injection device with a cleaning chamber |
| CN108368163A (zh) | 2015-08-25 | 2018-08-03 | 诺和诺德股份有限公司 | 新型胰岛素衍生物及其医学用途 |
| PL239062B1 (pl) | 2016-01-22 | 2021-11-02 | Inst Biotechnologii I Antybiotykow | Sposób wytwarzania insuliny i jej pochodnych |
| WO2018024186A1 (zh) | 2016-08-02 | 2018-02-08 | 江苏恒瑞医药股份有限公司 | 一种人胰岛素或其类似物的酰化衍生物 |
| JP7158378B2 (ja) | 2016-09-23 | 2022-10-21 | ハンミ ファーマシューティカル カンパニー リミテッド | インスリン受容体との結合力が減少された、インスリンアナログ及びその用途 |
| CA3294636A1 (en) | 2016-11-21 | 2026-02-10 | Case Western Reserve University | Rapid-acting insulin analogues of enhanced stability |
| WO2018107117A1 (en) * | 2016-12-09 | 2018-06-14 | Akston Biosciences Corporation | Insulin-fc fusions and methods of use |
| PE20210857A1 (es) | 2016-12-16 | 2021-05-18 | Novo Nordisk As | Composiciones farmaceuticas que contienen insulina |
| CN110545849A (zh) | 2017-02-03 | 2019-12-06 | 韩美药品株式会社 | 具有增加的持续性的生理活性物质的缀合物及其应用 |
| KR102629006B1 (ko) | 2017-03-23 | 2024-01-25 | 한미약품 주식회사 | 인슐린 수용체와의 결합력이 감소된 인슐린 아날로그의 결합체 및 이의 용도 |
| JOP20190273A1 (ar) | 2017-05-26 | 2019-11-24 | Lilly Co Eli | مركب إنسولين معالج بأسيل |
| KR20190036956A (ko) | 2017-09-28 | 2019-04-05 | 한미약품 주식회사 | 지속형 단쇄 인슐린 아날로그 및 이의 결합체 |
| JP2021014409A (ja) * | 2017-11-21 | 2021-02-12 | 京都薬品工業株式会社 | タンパク質結合性薬物 |
| US11413352B2 (en) | 2017-12-18 | 2022-08-16 | Merck, Sharp & Dohme LLC | Conjugate based systems for controlled insulin delivery |
| KR20210102347A (ko) | 2018-12-11 | 2021-08-19 | 사노피 | 인슐린 수용체 결합 친화성이 감소된 인슐린 유사체 |
| KR20220112817A (ko) | 2019-12-10 | 2022-08-11 | 사노피 | 설폰아미드 및 폴리펩티드의 콘주게이트를 형성하는 방법 |
-
2019
- 2019-12-10 KR KR1020217021396A patent/KR20210102347A/ko not_active Ceased
- 2019-12-10 WO PCT/EP2019/084433 patent/WO2020120479A1/en not_active Ceased
- 2019-12-10 SG SG11202106167XA patent/SG11202106167XA/en unknown
- 2019-12-10 US US16/709,208 patent/US11098102B2/en active Active
- 2019-12-10 MX MX2021006970A patent/MX2021006970A/es unknown
- 2019-12-10 AU AU2019398579A patent/AU2019398579A1/en not_active Abandoned
- 2019-12-10 KR KR1020217021394A patent/KR20210102345A/ko not_active Withdrawn
- 2019-12-10 SG SG11202106166TA patent/SG11202106166TA/en unknown
- 2019-12-10 MX MX2021006972A patent/MX2021006972A/es unknown
- 2019-12-10 JP JP2021533149A patent/JP2022513776A/ja active Pending
- 2019-12-10 TW TW108145067A patent/TW202039438A/zh unknown
- 2019-12-10 EP EP19816341.2A patent/EP3894435A1/en active Pending
- 2019-12-10 CA CA3122632A patent/CA3122632A1/en active Pending
- 2019-12-10 EP EP19816338.8A patent/EP3893934B1/en active Active
- 2019-12-10 MX MX2021006969A patent/MX2021006969A/es unknown
- 2019-12-10 TW TW108145066A patent/TW202039539A/zh unknown
- 2019-12-10 WO PCT/EP2019/084427 patent/WO2020120477A1/en not_active Ceased
- 2019-12-10 EP EP19816708.2A patent/EP3894391A1/en active Pending
- 2019-12-10 BR BR112021011050-0A patent/BR112021011050A2/pt not_active IP Right Cessation
- 2019-12-10 CN CN201980091275.1A patent/CN113396157A/zh active Pending
- 2019-12-10 BR BR112021011156-5A patent/BR112021011156A2/pt not_active IP Right Cessation
- 2019-12-10 KR KR1020217021395A patent/KR20210102346A/ko not_active Ceased
- 2019-12-10 WO PCT/EP2019/084400 patent/WO2020120463A1/en not_active Ceased
- 2019-12-10 CA CA3122636A patent/CA3122636A1/en active Pending
- 2019-12-10 CA CA3122637A patent/CA3122637A1/en active Pending
- 2019-12-10 SG SG11202106168VA patent/SG11202106168VA/en unknown
- 2019-12-10 CN CN201980091302.5A patent/CN113423691A/zh active Pending
- 2019-12-10 JP JP2021533153A patent/JP2022511567A/ja active Pending
- 2019-12-10 AU AU2019398658A patent/AU2019398658A1/en not_active Abandoned
- 2019-12-10 TW TW108145065A patent/TW202039437A/zh unknown
- 2019-12-10 BR BR112021011099-2A patent/BR112021011099A2/pt not_active IP Right Cessation
- 2019-12-10 CN CN201980091301.0A patent/CN113395982A/zh active Pending
- 2019-12-10 JP JP2021533148A patent/JP2022513775A/ja active Pending
- 2019-12-10 AU AU2019398402A patent/AU2019398402A1/en not_active Abandoned
-
2021
- 2021-05-25 US US17/329,558 patent/US12195510B2/en active Active
- 2021-06-07 PH PH12021551339A patent/PH12021551339A1/en unknown
- 2021-06-08 IL IL283803A patent/IL283803A/en unknown
- 2021-06-08 CO CONC2021/0007453A patent/CO2021007453A2/es unknown
- 2021-06-08 IL IL283800A patent/IL283800A/en unknown
- 2021-06-08 IL IL283801A patent/IL283801A/en unknown
-
2024
- 2024-12-05 US US18/970,367 patent/US20250206798A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021006970A (es) | Analogos de insulina que tienen una afinidad de union disminuida al receptor de insulina. | |
| EP3764834A4 (en) | Harness connection arrangement | |
| EP3834132A4 (en) | Region proposal with tracker feedback | |
| AU2017240185A1 (en) | Photosensitive dispersion and use thereof | |
| HK1217023A1 (zh) | 新型抗体 | |
| MX2021014038A (es) | Interfaz de conexion mecanica. | |
| BR112019005637A2 (pt) | análogos da insulina com afinidade reduzida para o receptor de insulina e seu uso | |
| MX2021000555A (es) | Tratamiento antidiabetico cardiovascular seguro. | |
| EP3821748B8 (en) | Buckle assembly | |
| GB201903062D0 (en) | Fuel control system | |
| EP4043613A4 (en) | CORROSION RESISTANT ELEMENT | |
| GB201811704D0 (en) | A connector stud | |
| EP3984081A4 (en) | BATTERY ARRANGEMENT | |
| MX2019011297A (es) | Complejo de analogo de insulina con afinidad reducida por el receptor de insulina y uso del mismo. | |
| EP4043565A4 (en) | MODIFIED HETERONUCLEIC ACID | |
| EP3781112A4 (en) | MOVEMENT AID DEVICE | |
| GB2525549A (en) | Collaborating robots | |
| EP3958407A4 (en) | FITTINGS SET | |
| EP3938787A4 (en) | AUTOANTIBODIES AS BIOMARKERS OF TESTIC CANCER-ASSOCIATED PARANEOLASTIC ENCEPHALITIS | |
| EP3685299A4 (en) | REGULATION OF THE MODIFICATION | |
| MX2023010036A (es) | Ensamblaje de abrazadera. | |
| AR117300A1 (es) | Análogos de insulina con afinidad de unión al receptor de insulina reducida | |
| EP3815703A4 (en) | PROMOTER OF PRODUCTION OF INTERLEUKIN-6, 10 | |
| MY176523A (en) | Modified colostrum protein and application thereof | |
| AU2019902274A0 (en) | Fuel-Air Regulator Location |